DIVIS LABORATORIES
|
DIVIS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 68.69 | 111.53 | 74.75 | 51.86 | 50.96 |
| CEPS(Rs) | 81.62 | 123.26 | 84.38 | 58.87 | 57.32 |
| DPS(Rs) | 30.00 | 30.00 | 20.00 | 16.00 | 16.00 |
| Book NAV/Share(Rs) | 480.96 | 441.82 | 350.15 | 275.38 | 262.09 |
| Tax Rate(%) | 23.02 | 19.63 | 25.57 | 24.34 | 27.08 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 30.30 | 43.18 | 40.92 | 33.41 | 37.60 |
| EBIT Margin(%) | 30.32 | 41.00 | 38.16 | 33.48 | 37.33 |
| Pre Tax Margin(%) | 30.29 | 40.98 | 38.13 | 33.35 | 37.24 |
| PAT Margin (%) | 23.32 | 32.94 | 28.38 | 25.23 | 27.15 |
| Cash Profit Margin (%) | 27.71 | 36.40 | 32.04 | 28.64 | 30.54 |
| Performance Ratios | |||||
| ROA(%) | 12.37 | 22.77 | 19.07 | 15.11 | 15.78 |
| ROE(%) | 14.89 | 28.16 | 23.90 | 19.30 | 21.00 |
| ROCE(%) | 19.36 | 35.06 | 32.07 | 25.36 | 28.50 |
| Asset Turnover(x) | 0.53 | 0.69 | 0.67 | 0.60 | 0.58 |
| Sales/Fixed Asset(x) | 1.30 | 1.74 | 1.70 | 1.77 | 1.99 |
| Working Capital/Sales(x) | 0.95 | 1.26 | 1.38 | 1.45 | 1.31 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.77 | 0.57 | 0.59 | 0.56 | 0.50 |
| Receivable days | 98.41 | 83.26 | 80.66 | 86.18 | 79.78 |
| Inventory Days | 136.05 | 100.99 | 104.66 | 121.62 | 114.41 |
| Payable days | 93.12 | 95.88 | 106.32 | 93.73 | 90.34 |
| Valuation Parameters | |||||
| PER(x) | 41.14 | 39.49 | 48.56 | 38.33 | 33.42 |
| PCE(x) | 34.62 | 35.73 | 43.02 | 33.76 | 29.71 |
| Price/Book(x) | 5.88 | 9.97 | 10.37 | 7.22 | 6.50 |
| Yield(%) | 1.06 | 0.68 | 0.55 | 0.81 | 0.94 |
| EV/Net Sales(x) | 9.11 | 12.73 | 13.52 | 9.76 | 9.14 |
| EV/Core EBITDA(x) | 26.09 | 28.54 | 32.22 | 26.17 | 22.28 |
| EV/EBIT(x) | 29.86 | 30.95 | 35.31 | 28.84 | 24.31 |
| EV/CE(x) | 4.77 | 7.80 | 8.27 | 5.59 | 5.14 |
| M Cap / Sales | 9.66 | 13.05 | 13.83 | 9.78 | 9.14 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -13.31 | 28.56 | 29.20 | 9.06 | 27.10 |
| Core EBITDA Growth(%) | -32.10 | 36.71 | 45.25 | -0.78 | 47.41 |
| EBIT Growth(%) | -35.68 | 38.13 | 46.07 | -1.78 | 50.75 |
| PAT Growth(%) | -38.41 | 49.19 | 44.15 | 1.76 | 54.24 |
| EPS Growth(%) | -38.41 | 49.19 | 44.15 | 1.76 | 54.24 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.02 |
| Current Ratio(x) | 6.36 | 3.92 | 3.93 | 3.06 | 5.49 |
| Quick Ratio(x) | 4.40 | 2.76 | 2.69 | 2.04 | 3.40 |
| Interest Cover(x) | 1,209.48 | 1,842.75 | 1,270.54 | 255.83 | 397.38 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹100,086.9 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,001.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,813.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,325.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
| MANKIND PHARMA | ₹95,896.9 Cr | NA | NA | NA | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | -1.6% |
-7% |
23.8% |
| SENSEX | 0.5% |
1.4% |
23.5% |
You may also like the below Video Courses
